|Place of Origin:||China|
|Model Number:||500mg, 850mg|
|Minimum Order Quantity:||One million tablets|
|Payment Terms:||L/C, T/T|
|Supply Ability:||One million tablets per day|
|Product:||Metformin Hydrochloride Tablets||Specification:||500mg, 850mg|
Diabetes Oral Medications Metformin Hydrochloride Tablets 500 mg 850mg
Product : Metformin Hydrochloride Tablets
Specification : 500mg, 850mg
Standard : BP, USP
Packing : 10’s/blister
Metformin hydrochloride tablets and metformin hydrochloride Extended-Release Tablets are oral antihyperglycemic drugs used in the management of type 2 diabetes.
Indications and Usage
Metformin hydrochloride Tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus.
Metformin hydrochloride Extended-Release Tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Metformin is an oral antihyperglycemic agent that improves glucose tolerance in patients with NIDDM, lowering both basal and postprandial plasma glucose. Metformin is not chemically or pharmacologically related to any other class of oral antihyperglycemic agents. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with NIDDM or healthy subjects and does not cause hyperinsulinemia. Metformin does not affect insulin secretion.
Mechanism of Action
Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms of action are different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects (except in special circumstances, see PRECAUTIONS) and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.